Lung Cancer | Specialty

Chemotherapy-Induced Myelosuppression in SCLC: CDK4/6 Inhibition

September 16th 2020

Analyses of CDK4/6 Inhibitors for Myelopreservation

September 16th 2020

CDK4/6 Inhibitors and Myelopreservation

September 16th 2020

Chemotherapy-Induced Myelosuppression & COVID-19

September 16th 2020

Management of Chemo-Induced Myelosuppression

September 16th 2020

Chemotherapy Use & Chemotherapy-Induced Myelosuppression

September 16th 2020

Sequencing and Resistance Mechanism Challenges Arise in Biomarker-Driven NSCLC

September 15th 2020

Kartik Konduri, MD, discussed current treatment options that are available for patients with ALK, ROS1, and RET–positive NSCLC, as well as promising agents in the pipeline.

Osimertinib Eclipses Current Treatment Options in EGFR-Mutant NSCLC

September 14th 2020

Sawsan Rashdan, MD, discusses the current treatment paradigm of patients with resectable and metastatic EGFR-mutant NSCLC.

FDA Approves Oncomine Dx Target Test Companion Diagnostic for Pralsetinib in RET+ NSCLC

September 11th 2020

The FDA has approved the Oncomine Dx Target Test as a companion diagnostic to identify patients with RET fusion–positive non¬–small lung cancer who are candidates to receive the recently approved targeted therapy pralsetinib.

Dr. Chiang on the Management of Immune-Related AEs in Lung Cancer

September 10th 2020

Anne Chiang, MD, PhD, discusses the management of ​immune-related adverse effects in lung cancer. 

Daiichi Sankyo, Gustave Roussy Research Partnership Holds Promise for NSCLC, Breast Cancer Paradigms

September 8th 2020

A multi-year, multi-study research collaboration between Daiichi Sankyo and Gustave Roussy Cancer Center will support the clinical, translational, and preclinical evaluation of 2 of the company’s lead antibody-drug conjugates: DS-1062 in advanced non–small cell lung cancer, and patritumab deruxtecan in metastatic breast cancer.

Dr. Konduri on Sequencing Challenges in ALK+ NSCLC

September 8th 2020

Kartik Konduri, MD, discusses remaining sequencing challenges in ALK-positive non–small cell lung cancer.

Expanded Lung Cancer Screening Criteria Would Boost Survival Outcomes

September 5th 2020

Under a draft recommendation proposed by the US Preventive Services Task Force, individuals who are at a high risk for developing lung cancer because of their smoking history would begin annual screening with low-dose computed tomography at aged 50 years.

Dr. Subbiah on the FDA Approval of Pralsetinib in RET+ NSCLC

September 5th 2020

Vivek Subbiah, MD, discusses the clinical implications of the approval of pralsetinib in patients with RET fusion–positive non–small cell lung cancer.

FDA Approves Pralsetinib for Metastatic RET+ NSCLC

September 5th 2020

The FDA has approved pralsetinib for the treatment of patients with metastatic, RET fusion–positive non-small cell lung cancer.

Dr. Rizvi on the Utility of Trastuzumab Deruxtecan in NSCLC

September 3rd 2020

Naiyer A. Rizvi, MD, discusses the utility of fam-trastuzumab deruxtecan-nxki  in non–small cell lung cancer.

Dr. Pennell on Remaining Challenges in NSCLC

September 3rd 2020

Nathan A. Pennell, MD, PhD, discusses remaining challenges in non–small cell lung cancer.

Capmatinib Continues to Show Significant Antitumor Activity in METex14+ NSCLC

September 3rd 2020

Capmatinib continued to elicit a significant, durable responses in patients with metastatic non–small cell lung cancer whose tumors harbor a MET exon14 skipping mutation.

Dr. Rizvi on Utilizing Molecular Characteristics to Inform Treatment Decisions in NSCLC

September 2nd 2020

Naiyer A. Rizvi, MD, discusses treatment approaches in non–small cell lung cancer.

Selpercatinib Demonstrates Durable Efficacy and Intracranial Activity in RET+ NSCLC

September 2nd 2020

The RET inhibitor selpercatinib was shown to have durable efficacy with mostly low-grade adverse effects in patients with RET fusion–positive non–small-cell lung cancer.